Mylan

Mylan

Mylan

Official page for Mylan, where we work around the clock and around the globe to help provide 7 billion people access to high quality medicine
Follow us
Alexa global traffic share
Twitter followers
Team Size
10000+
Employees
MedCity News

Biogen fends off Mylan’s challenge to patent on top-selling multiple sclerosis drug

Reuters Top News

Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe

Reuters Top News

Denmark's Novo Nordisk files lawsuit against Mylan over patent

Reuters Top News , Xconomy

Pfizer to merge generics unit with Mylan; seeks to sharpen cancer...

PE HUB

Mylan to merge with Upjohn

Reuters Top News

Pfizer in talks to merge off-patent drugs business with Mylan: source

Bloomberg

Mylan Critic Blumenthal Asks FDA to Help End EpiPen Shortage

Health Manufacturing
Ars Technica

72% of Mylan shareholders think Heather Bresch is doing great—just overpaid

Strategy
Ars Technica

Mylan board survives shareholder vote, but gets pushback on its compensation

Strategy
Ars Technica

With help of coal tax credits, Mylan had a negative 294-percent tax rate in 2016

Stock markets Strategy
Ars Technica

Mylan chairman: Drug pricing critics ought to go copulate with themselves

Costs Communities Health
Quartz

How Mylan got away with overcharging Medicaid $1.3 billion for EpiPen

Health Privacy
Ars Technica

Mylan shareholders revolt, say directors’ greed has gone too far

Stock markets
Ars Technica

Mylan bullied, sued states to get them to use EpiPens, court documents show

Legal Health
Ars Technica

FDA lashes out at Mylan for dismal quality control at HIV drug facility

Health
Ars Technica

Despite what Mylan said, its price hikes hit patients’ wallets hard

Health Costs Earnings
The Verge

EpiPen maker Mylan is under investigation by the Federal Trade Commission

US elections
Ars Technica

For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million

Health Costs Privacy
Slashdot

Feds Go After Mylan For Scamming Medicaid Out of Millions On EpiPen Pricing

Ars Technica

Mylan CEO misled lawmakers about EpiPen profits—they’re 66% higher

Earnings